Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

GenFleet's Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors
CompanyDrug

GenFleet’s Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that multiple innovative combination therapies of its oral pan‑RAS inhibitor GFH276 have received Clinical Trial Authorizations (CTA) from the Center for Drug Evaluation…

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors

CompanyDrug

CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces

CompanyDeals

LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305

CompanyDrug

Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA

CompanyDrug

CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo

CompanyDrug

Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer

CompanyDrug

Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC

CompanyDrug

Sichuan Kelun Pharmaceutical’s A166 Anti-HER2 ADC NDA Accepted for Review by NMPA

Show More